Study: SBRT Delivers 98.6% Cure Rate at Five-Year Followup

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Oxybutynin reduces hot flashes during prostate cancer treatment, randomized study finds

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer.

February 06, 2026

Vol.52 No.05

Clinical Roundup

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

January 30, 2026

Vol.52 No.04

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Prostate cancer remains a formidable challenge, particularly in its advanced stages, where bone metastases and treatment resistance dominate outcomes. At City of Hope, our focus is on leveraging immunotherapy to transform this landscape.

January 23, 2026

Vol.52 No.03

By Tanya Dorff

Clinical Roundup

Researchers develop tool that can identify high- and low-risk metastatic prostate cancer patients earlier

A multi-institutional research team has developed one of the first validated tools to predict before treatment if a patient will have a favorable biochemical response in patients with metastatic hormone-sensitive prostate cancer.

January 23, 2026

Vol.52 No.03

Clinical Roundup

Researchers identify ideal duration of prostate cancer hormone therapy

Researchers set out to answer a question: what is the ideal duration of hormone therapy for the treatment of prostate cancer? Hormone therapy is commonly combined with radiation therapy for prostate cancer, but patients are often unsure how long it should be continued and why.

January 23, 2026

Vol.52 No.03

Study: SBRT Delivers 98.6% Cure Rate at Five-Year Followup

YOU MAY BE INTERESTED IN

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

Oxybutynin reduces hot flashes during prostate cancer treatment, randomized study finds

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Researchers develop tool that can identify high- and low-risk metastatic prostate cancer patients earlier

Researchers identify ideal duration of prostate cancer hormone therapy

Renew today!

Subscriber content

Never miss an issue!

Login